Akt Inhibitor VII, TAT-Akt-in

A cell-permeable and reversible version of the Akt Inhibitor VI, Akt-in (Cat. No. 124013) fused with the protein transduction domain TAT that displays antitumor properties. Inhibits the phosphorylation of Akt selectively in HEK 293 and QRsP-11 fibrosarcoma cells stimulated with PDGF (complete inhibition at ~50 µM) with minimal inhibition towards PKA, PKC, PDK1, p42/44 MAPK, or p38 MAPK. Shown to prevent the proliferation of T4 cells, and tumor growth in syngeneic C57BL/6 mice.

A cell-permeable and reversible version of the Akt Inhibitor VI, Akt-in (Cat. No. 124013) fused with the protein transduction domain TAT. Selectively inhibits the phosphorylation of Akt selectively in HEK 293 and QRsP-11 fibrosarcoma cells stimulated with PDGF (complete inhibition at ~50 µM) with minimal inhibition towards PKA, PKC, PDK1, p42/44 MAPK, or p38 MAPK. Shown to prevent the proliferation of T4 cells and tumor growth in syngeneic C57BL/6 mice at 2 µM/mouse without any adverse effect.

Cell permeable: yes

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 50 µM against Akt

Packaged under inert gas

Toxicity: Carcinogenic / Teratogenic (D)

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-Val-Thr-Asp-His-Pro-Asp-Arg-Leu-Trp-Ala-Trp-Glu-Lys-Phe-OH

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany